Core Points - BiomX Inc. announced a one-for-nineteen reverse stock split of its common stock, effective November 25, 2025 [1][2][3] - The reverse stock split was approved by stockholders at the 2025 Annual Meeting on October 16, 2025, with the final ratio set by the Board of Directors on November 13, 2025 [2] - Following the reverse stock split, the number of outstanding shares will decrease from approximately 29,006,165 to about 1,526,640 [4] Company Overview - BiomX is a clinical-stage company focused on developing natural and engineered phage therapies to target specific pathogenic bacteria [5] - The company utilizes its BOLT platform to customize phage compositions aimed at treating chronic diseases with significant unmet medical needs [5]

Core Viewpoint - BiomX Inc. announced a one-for-nineteen reverse stock split of its common stock, effective November 25, 2025, to enhance its stock price and maintain compliance with NYSE American listing requirements [1][2][3]. Group 1: Reverse Stock Split Details - The reverse stock split will convert nineteen current shares into one new share, affecting all stockholders uniformly without altering their percentage ownership interest [3][4]. - The number of outstanding shares will decrease from approximately 29,006,165 to about 1,526,640, with adjustments for fractional shares [4]. - No fractional shares will be issued; stockholders entitled to fractional shares will receive an additional fraction to round up to the next whole share [4]. Group 2: Company Background - BiomX is a clinical-stage company focused on developing natural and engineered phage therapies targeting harmful bacteria for chronic diseases with significant unmet needs [5]. - The company utilizes its BOLT platform to customize phage compositions against proprietary bacterial targets [5].

Core Insights - BiomX Inc. will report its third quarter 2025 financial results and program updates on November 12, 2025, before the U.S. financial markets open [1] - A conference call and live audio webcast will be held at 8:30 a.m. ET on the same day to discuss the financial results and program updates [1][2] Company Overview - BiomX is a clinical-stage company focused on developing natural and engineered phage therapies targeting specific pathogenic bacteria for chronic diseases with significant unmet needs [4] - The company utilizes its BOLT ("BacteriOphage Lead to Treatment") platform to customize phage compositions against proprietary bacterial targets [4]